- Home
- TAC vs LNTH Comparison
TAC vs LNTH Comparison
Compare TAC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- LNTH
- Stock Information
- Founded
- TAC 1909
- LNTH 1956
- Country
- TAC Canada
- LNTH United States
- Employees
- TAC N/A
- LNTH N/A
- Industry
- TAC Electric Utilities: Central
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TAC Utilities
- LNTH Health Care
- Exchange
- TAC Nasdaq
- LNTH Nasdaq
- Market Cap
- TAC 4.3B
- LNTH 3.9B
- IPO Year
- TAC N/A
- LNTH 2015
- Fundamental
- Price
- TAC $17.26
- LNTH $56.19
- Analyst Decision
- TAC Strong Buy
- LNTH Buy
- Analyst Count
- TAC 4
- LNTH 6
- Target Price
- TAC $21.63
- LNTH $74.50
- AVG Volume (30 Days)
- TAC 2.5M
- LNTH 1.4M
- Earning Date
- TAC 11-06-2025
- LNTH 11-06-2025
- Dividend Yield
- TAC 1.04%
- LNTH N/A
- EPS Growth
- TAC N/A
- LNTH N/A
- EPS
- TAC N/A
- LNTH 3.77
- Revenue
- TAC $1,838,165,207.00
- LNTH $1,520,653,000.00
- Revenue This Year
- TAC N/A
- LNTH N/A
- Revenue Next Year
- TAC N/A
- LNTH $2.25
- P/E Ratio
- TAC N/A
- LNTH $14.87
- Revenue Growth
- TAC N/A
- LNTH 5.75
- 52 Week Low
- TAC $7.82
- LNTH $47.25
- 52 Week High
- TAC $17.69
- LNTH $118.21
- Technical
- Relative Strength Index (RSI)
- TAC 76.45
- LNTH 55.01
- Support Level
- TAC $16.24
- LNTH $54.99
- Resistance Level
- TAC $17.10
- LNTH $57.94
- Average True Range (ATR)
- TAC 0.65
- LNTH 1.66
- MACD
- TAC 0.04
- LNTH 0.48
- Stochastic Oscillator
- TAC 86.20
- LNTH 78.55
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.